Glox Therapeutics develops engineered protein bacteriocins that precisely target drug‑resistant Gram‑negative pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Leveraging a discovery platform built on two decades of bacteriocin research, the company creates high‑specificity antibiotics that minimize off‑target effects, preserve beneficial microbiota, and reduce the risk of resistance development.
Funding
$613.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Antimicrobial resistance (AMR) is increasing the prevalence of drug‑resistant bacterial infections such as those caused by Pseudomonas aeruginosa and Klebsiella pneumoniae, leading to higher mortality and limited treatment options.
Solution
Glox Therapeutics leverages a discovery platform built on two decades of bacteriocin research to engineer precision protein antibiotics that selectively kill resistant pathogens. By tailoring bacteriocin structures to specific bacterial targets, the company creates therapeutics that minimize off‑target effects and reduce the likelihood of resistance development. These engineered bacteriocins are designed for clinical development as novel treatments for serious infections where existing antibiotics fail. The platform enables rapid iteration of candidate molecules and supports a pipeline focused on high‑priority AMR organisms.
Target Audience
Primary customers are pharmaceutical companies and healthcare providers seeking new therapeutic options for treating infections caused by multidrug‑resistant Gram‑negative bacteria.
Features
- Engineered protein bacteriocins customized to bind and kill specific drug‑resistant bacteria
- Structure‑guided design informed by extensive bacteriocin functional and structural data
- High specificity reduces impact on beneficial microbiota and lowers selective pressure for resistance
- Scalable recombinant production platform for consistent manufacturing of protein therapeutics
- Preclinical pipeline targeting Pseudomonas aeruginosa and Klebsiella pneumoniae, with additional candidates in development